The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]
Important Dates
no event
Latest News
Prizes awarded to Factor-H
Congratulations to Factor-H for the hugely well-deserved recognition of their work from Amgen (2024 Amgen/MIT Solve award) and MDS (Public Service Award). Read more here: Factor-H is Awarded the 2024 Amgen Prize! and Factor-H President receives the 2024 Public Service Award from the MDS. […]
Alnylam Pharmaceuticals Global study endorsed* by EHDN
Study aims and goal: ALN-HTT02 is a novel C16-siRNA conjugate for huntingtin-lowering. This Phase Ib study aims to evaluate ALN-HTT02 in adults with Huntington’s Disease. No. of study participants and sites: The study plans to enrol participants from ~20 sites in Canada, Germany, UK and US. For further information see the clinical trial registration. *EHDN […]
Photo Exhibition: September 17-28, Taufkirchen (Vils), Germany
Beyond the inheritance – Mas allá de la herencia: a photo exhibiton by Vladimir Marchano […]
EHDN Election 2024
[…]
EHDN Newsletter – 52nd edition
The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]
Clinical trial update: PTC Therapeutics reported initial 12-month data from the PIVOT-HD trial
On 20 June 2024, PTC Therapeutics reported initial 12-month data from the PIVOT-HD trial, showing dose-dependent mHTT lowering in the blood and cerebrospinal fluid, and early evidence for potential clinical benefits. For more information, click here. […]
Clinical trial update: Sage Therapeutics reported topline data on the Phase 2 SURVEYOR study
On 11 June 2024, Sage Therapeutics reported topline data on the Phase 2 SURVEYOR study confirming that the primary endpoint was met and no new safety concerns emerged. Read the full press release. […]
Video Postcard – 19th Annual HD Therapeutics Conference from Palm Springs
The Postcard from Palm Springs video from the 19th Annual HD Therapeutics Conference held February 26 — 29, 2024, in Palm Springs, California, is now available to view online. […]
EHDN PODCAST | Juvenile and Paediatric HD
Episode #1: Introduction: What is Juvenile and Pediatric HD? […]